Mostrar el registro sencillo del ítem
dc.contributor.author | Medrano, Luz Maria | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Salgüero Fernandez, Sergio | |
dc.contributor.author | González-García, Juan | |
dc.contributor.author | Díez, Cristina | |
dc.contributor.author | Hontañón, Víctor | |
dc.contributor.author | Garcia-Broncano, Pilar | |
dc.contributor.author | Ibañez-Samaniego, Luis | |
dc.contributor.author | Bellón, José M | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2021-03-09T09:33:23Z | |
dc.date.available | 2021-03-09T09:33:23Z | |
dc.date.issued | 2021-02 | |
dc.identifier.citation | Front Med (Lausanne) . 2021 Feb 1;8:615342. | es_ES |
dc.identifier.issn | 2296-858X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/12153 | |
dc.description.abstract | Background: Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in HIV-infected patients with advanced HCV-related cirrhosis. Methods: We performed an observational study of 50 patients with advanced cirrhosis who received DAAs therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Epidemiological and clinical data were collected through an online form. Liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), and Child-Pugh-Turcotte (CTP) were evaluated by physicians. Plasma biomarkers were measured by multiplex immunoassay. Results: We found significant decreases in severity scores of liver disease [LSM (q-value < 0.001), HVPG (q-value = 0.011), and CTP (q-value = 0.045)] and plasma biomarkers [LBP (q-value < 0.001), IP-10 (q-value < 0.001), IL-8 (q-value < 0.001), IL-18 (q-value < 0.001), IL-1RA (q-value = 0.013), OPG (q-value < 0.001), sVCAM-1 (q-value < 0.001), sICAM-1 (q-value < 0.001), PAI-1 (q-value = 0.001), and VEGF-A (q-value = 0.006)]. We also found a significant direct association between the change in LSM values and the change in values of LBP (q-value < 0.001), IP-10 (q-value < 0.001), MCP-1 (q-value = 0.008), IL-8 (q-value < 0.001), IL-18 (q-value < 0.001), OPG (q-value = 0.004), sVCAM-1 (q-value < 0.001), sICAM-1 (q-value < 0.001), and PAI-1 (q-value = 0.002). For CTP values, we found significant positive associations with IP-10 (q-value = 0.010), IL-6 (q-value = 0.010), IL-1RA (q-value = 0.033), and sICAM-1 (q-value = 0.010). Conclusion: The HCV eradication with all-oral DAAs in HIV/HCV-coinfected patients with advanced cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis). The decrease in plasma biomarkers was mainly related to the reduction in LSM values. | es_ES |
dc.description.sponsorship | This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JG-G, CP17CIII/00007 and PI18CIII/00028 to AJ-S, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and cofunded by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT16/00100. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HIV/HCV co-infected patients | es_ES |
dc.subject | Angiogenesis | es_ES |
dc.subject | Chronic hepatitis C (CHC) | es_ES |
dc.subject | Cirrhosis | es_ES |
dc.subject | Coagulopathy | es_ES |
dc.subject | Direct-acting antiviral (DAA) therapy | es_ES |
dc.subject | Inflammation | es_ES |
dc.title | Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 33598470 | es_ES |
dc.format.volume | 8 | es_ES |
dc.format.page | 615342 | es_ES |
dc.identifier.doi | 10.3389/fmed.2021.615342 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | European Regional Development Fund | |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fmed.2021.615342 | es_ES |
dc.identifier.journal | Frontiers in medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI20/00474 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17/00657 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI20/00507 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17/00903 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CP17CIII/00007 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI18CIII/00028 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI20CIII/00004 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17CIII/00003 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD16CIII/0002/0002 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD16/0025/0018 | es_ES |
dc.rights.accessRights | open access | es_ES |